WALTHAM, Mass.--()--Histogenics Corp., a biologics company that combines cell therapy and tissue engineering technologies to develop highly innovative products primarily for sports-related and orthopedic tissue repair and regeneration, is proudly supporting this year’s Major League Soccer (MLS) Medical Symposium. The MLS Symposium will bring together sports medicine physicians, orthopedic surgeons, primary care physicians and athletic trainers to educate and raise awareness on a range of sport-related injuries.
“We are proud to support this year’s MLS Medical Symposium”
“We are proud to support this year’s MLS Medical Symposium,” said Patrick O’Donnell, President and Chief Executive Officer of Histogenics. “Through the MLS Symposium’s educational programming, we will help to raise both awareness and education surrounding innovative treatments for sports-related injuries. We believe that regenerative medicine treatments will play a pivotal role in the future treatment of cartilage injuries to the knee. Our research shows that approximately 40% of soccer injuries are knee injuries so our participation in the symposium is a great fit."
Histogenics has successfully completed Phase 1 and Phase 2 clinical trials and is currently enrolling in the Phase 3 study for NeoCart®, an investigational personalized cartilage tissue implant to treat knee injuries. NeoCart® uses regenerative medicine technology to create personalized hyaline cartilage tissue from a patient’s own cells.
The MLS Medical Symposium will be held on January 12th in Ft. Lauderdale, FL. The Symposium is jointly sponsored by the Hospital for Special Surgery Office of Continuing Medical Education and Major League Soccer.
Histogenics is a leading regenerative medicine company that combines cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. In May of 2011, Histogenics acquired Israeli cell-therapy company ProChon BioTech. Histogenics’ flagship products focus on the treatment of active patients suffering from articular cartilage derived pain and immobility. The Company takes an interdisciplinary approach to engineering neocartilage that looks, acts and lasts like hyaline cartilage. It is developing new treatments for sports injuries and other orthopedic conditions, where demand is growing for long-term alternatives to joint replacement. Histogenics has successfully completed Phase 1 and Phase 2 clinical trials in which the NeoCart autologous tissue implant is compared to standard microfracture surgery. Based in Waltham, Massachusetts, the company is privately held. For more information, visit www.histogenics.com.